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Half a century ago, an immunologist named N. Avrion Mitchison showed that 
lymphocytes—then thought to be useless—triggered tumor rejection in mice.
As recently as the 1940s, immunologists 
thought lymphocytes served no purpose. 
Antibodies, on the other hand, were all 
the rage. But this thinking started to 
change when a British group began to 
investigate the fate of tissue transplants.
One member of this group was 
Mitchison, a bright and independent-
minded student whose work was in-
spired by his Oxford University mentor, 
Peter Medawar. Medawar had discov-
ered that skin grafts given to patients 
with severe burns survived if derived 
from the patient’s own body, but with-
ered away if taken from a donor. A 
second graft from the same donor was 
rejected more quickly than the first. 
Medawar reproduced this phenomenon 
in rabbits and—as was customary at the 
time—believed antibodies to be re-
sponsible (1, 2).
Cells become suspects
Intrigued, Mitchison repeated the experi-
ment in mice using tumor transplants in-
stead of skin grafts, because tumors were 
easier to manipulate. His results were 
identical to Medawar’s—secondary tu-
mors were rejected more rapidly than 
first-time tumors—but his interpretation 
was different. Mitchison noticed that the 
transplanted mice had enlarged lymph 
nodes, and he recalled a similar observa-
tion by Karl Landsteiner and Melvin 
Chase in guinea pigs vaccinated with a 
bacterial antigen (3). In that study, the 
transfer of lymph node cells from vacci-
nated animals, but not antibody-contain-
ing serum, boosted the reaction of naive 
animals exposed to the antigen.
Mitchison thus wondered whether 
cells, rather than antibodies, were re-
sponsible for the accelerated tumor 
rejection in his mice. To distinguish 
between the two possibilities, he trans-
ferred either lymph node cells or serum 
from mice that had already rejected a 
tumor. Mice that received cells rejected 
tumors more quickly than both untreated 
mice and those that received serum, sug-
gesting that the lymph node cells were 
doing the work (4, 5).
Inspired by Mitchison’s finding, 
Medawar and colleagues Rupert Bill-
ingham and Leslie Brent found similar 
results in rabbits (6). Medawar had 
“never been that keen on antibodies,” 
recalls Mitchison, “they were simply 
the only mechanism known at the 
time. He certainly accepted—gladly—
my work”.
But questions remained about how 
the transferred cells acted. Did they 
attack the tumor directly? Or did they 
carry tumor antigens with them that 
prompted a response in the host?
Immunology meets genetics
The effect of the transferred cells dis-
a  ppeared after 10 to 20 days. Mitchison 
guessed that the host immune system 
was rejecting the foreign cells and thus 
switched to a new set of tools—the in-
bred mice of geneticists Clarence Cook 
Little and George Snell (Jackson Labo-
ratory, Maine). Bred over many genera-
tions, the strains were identical for 
genes now known as the major histo-
compatibility complex. This genetic 
parity allowed transferred lymph node 
cells to survive for many weeks after 
transfer without rejection.
Mitchison first confirmed that it 
was transferred lymphocytes, not anti-
bodies, that led to the quicker tumor 
rejection in the hosts, as rejection oc-
curred before the hosts could make 
their own antitumor antibodies. The 
effect was lost if the cells were killed by 
freezing before transfer, ruling out the 
possibility that transferred tumor anti-
gens were the trigger. Mitchison later 
showed that only the lymph nodes 
closest to the tumors in donor mice—
presumably those collecting and react-
ing to tumor fragments—contained the 
tumor-fighting cells.
The already strong case against anti-
bodies was further bolstered when 
Mitchison showed that serum antibodies, 
even if transferred with the lymphocytes, 
were unlikely to reach the tumor trans-
plant. His results, published in three 
papers in the Journal of Experimental 
Medicine (7, 8, 9), helped bring immu-
nology to a turning point: the recogni-
tion that lymphocytes were important.
The importance of lymphocytes was 
later solidified by Jim Gowans, who 
showed that lymphocytes circulated be-
tween blood and tissues and therefore 
could patrol the body (10). Jacques Miller 
then demonstrated that some lympho-
cytes developed in the thymus and were 
essential for fending off infections (11). 
Mitchison later returned to the UK 
where he was the first to show convinc-
ingly that T and B cells must cooperate to 
trigger antibody production (12).
REFERENCES
 1. Medawar,  P.B.  1944.  J. Anat. 78:176.
 2. Medawar,  P.B.  1945.  J. Anat. 79:157.
 3. Landsteiner, K., and M.W. Chase. 1942. 
Proc. Soc. Exp. Biol. 49:688–690.
 4. Mitchison,  N.A.  1953.  Nature. 171:267–268.
 5. Mitchison, N.A. 1954. Proc. R. Soc. Lond. B. 
Biol. Sci. 142:72.
  6.  Billingham, R.E., L. Brent, and P.B. Medawar. 
1954. Proc. R. Soc. Lond. B. Biol. Sci. 143:58.
 7. Mitchison,  N.A.  1955.  J. Exp. Med. 
102:157–177.
 8. Mitchison,  N.A.  1955.  J. Exp. Med. 
102:179–197.
 9. Mitchison,  N.A.  1955.  J. Exp. Med. 
102:199–204.
10.  Gowans, J.L. 1959. J. Physiol. 46:54–69.
11. Miller,  J.F.  1961.  Lancet. 2:748–749.
12. Mitchison, N.A. 2004. Nat. Rev. Immunol. 
4:308–312.
Text by Julie Clayton
Julie.p.clayton@blueyonder.co.uk
Avrion Mitchison says cheers to lymphocytes (1957).